CRVSのチャート
CRVSの企業情報
| symbol | CRVS |
|---|---|
| 会社名 | Corvus Pharmaceuticals Inc （コルバス・ファ―マシュ―ティカルズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 コーバス・ファーマスーティカル(Corvus Pharmaceuticals Inc.)は臨床段階のバイオ医薬品会社である。同社は免疫腫瘍療法の開発と商品化に従事する。同社は免疫チェックポイントを阻止し、免疫T細胞を再プログラミングする薬物と抗体を開発する。同社は4つの免疫腫瘍学プログラムのパイプラインがあり、そのうち3つは免疫応答を調節するアデノシン - 癌軸に焦点を当てる。同社のリード製品候補であるCPI-444は免疫チェックポイントであるアデノシンに対するA2A受容体の経口・小分子アンタゴニストである。他の製品にはモノクローナル抗CD73抗体であるアデノシン産生阻害剤、アデノシンA2Bアンタゴニスト及びインターロイキン-2（IL-2）誘導性T細胞キナーゼ（ITK）阻害剤を含む。 コルバス・ファ―マシュ―ティカルズは米国の臨床段階のバイオ医薬品企業。がん治療のための新薬の開発・商品化に注力する。主に、アデノシンの生産を阻害及び抑制することで、免疫反応の調整を促す免疫腫瘍学のパイプラインを構築。また、T細胞の活性化と分化を調節するための治療薬も開発中。本社はカリフォルニア州。 Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company. Corvus' lead product candidate is CPI-006, a humanized monoclonal antibody directed against CD73 that has exhibited immunomodulatory activity and activation of immune cells in preclinical studies. CPI-006 is being evaluated in a Phase 3 clinical trial for the treatment of hospitalized patients with COVID-19 and in a multicenter Phase 1/1b oncology clinical trial as a single agent, in combination with ciforadenant and pembrolizumab. The Company's second clinical program, CPI-818, is an investigational, oral, small molecule drug that selectively inhibited ITK in preclinical studies, and is in a multicenter Phase 1/1b clinical trial in patients with several types of T-cell lymphomas. Its third clinical program, ciforadenant (CPI-444), is an oral, small molecule inhibitor of the A2A receptor. |
| 本社所在地 | 863 Mitten Road Suite 102 Burlingame CA 94010 USA |
| 代表者氏名 | Richard A. Miller リチャード・A・ミラー |
| 代表者役職名 | Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者（CEO） |
| 電話番号 | +1 650-900-4520 |
| 設立年月日 | 41640 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2016年 |
| 従業員数 | 55人 |
| url | www.corvuspharma.com |
| nasdaq_url | https://www.nasdaq.com/symbol/crvs |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -51.16600 |
| 終値（lastsale） | 8.58 |
| 時価総額（marketcap） | 250517613.06 |
| 時価総額 | 時価総額（百万ドル） 248.47380 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 115.24880 |
| 当期純利益 | 当期純利益（百万ドル） -50.57800 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Corvus Pharmaceuticals Inc revenues was not reported. Net loss decreased 16% to $25.9M. Lower net loss reflects Research and development - Balancing val decrease of 18% to $20.3M (expense) General and administrative - Balancing decrease of 18% to $3.1M (expense) Interest income increase from $374K to $970K (income). Basic Earnings per Share excluding Extraordinary Items increased from -$1.52 to -$1.03. |
CRVSのテクニカル分析
CRVSのニュース
Corvus Pharmaceuticals, Inc. (CRVS) Q4 2022 Earnings Call Transcript 2023/03/29 02:55:16 Seeking Alpha
Corvus Pharmaceuticals, Inc. (NASDAQ:NASDAQ:CRVS) Q4 2022 Earnings Conference Call March 27, 2023 4:30 PM ETCompany ParticipantsZack Kubow - Investor Relations-Real ChemistryLeiv Lea -…
Corvus Pharmaceuticals GAAP EPS of -$0.21 beats by $0.02 2023/03/28 20:06:40 Seeking Alpha
Corvus Pharmaceuticals press release (CRVS): Q4 GAAP EPS of -$0.21 beats by $0.02.As of December 31, 2022, Corvus had cash, cash equivalents and marketable securities…
Corvus Pharmaceuticals Earnings Preview 2023/03/27 14:01:37 Benzinga
Corvus Pharmaceuticals (NASDAQ: CRVS ) is set to give its latest quarterly earnings report on Tuesday, 2023-03-28. Here''s what investors need to know before the announcement. Analysts estimate that Corvus Pharmaceuticals will report an earnings per share (EPS) of $-0.23. Corvus Pharmaceuticals bulls will hope to hear the company announce they''ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the … Full story available on Benzinga.com
Corvus Pharma''s HIV Candidate Shows Potential To Prevent Virus Re-Emergence 2023/02/21 17:34:40 Benzinga
Corvus Pharmaceuticals Inc (NASDAQ: CRVS ) announced new data demonstrating the potential of CPI-818, an ITK inhibitor, to reduce the need for chronic human immunodeficiency virus (HIV) therapy. For people living with HIV on antiretroviral therapy, HIV can be reduced to levels below detection limits, which enables the restoration and preservation of immune system function, reduces HIV-associated morbidity, … Full story available on Benzinga.com
Corvus Pharmaceuticals Announces New Data Demonstrating CPI-818’s (ITK Inhibitor) Potential to Block HIV Latency Reversal 2023/02/21 12:00:00 GlobeNewswire
Findings may provide a treatment that enables discontinuation of HIV antiretroviral therapy by preventing re-emergence of the virus
Corvus Pharma''s HIV Candidate Shows Potential To Prevent Virus Re-Emergence 2023/02/21 17:34:40 Benzinga
Corvus Pharmaceuticals Inc (NASDAQ: CRVS ) announced new data demonstrating the potential of CPI-818, an ITK inhibitor, to reduce the need for chronic human immunodeficiency virus (HIV) therapy. For people living with HIV on antiretroviral therapy, HIV can be reduced to levels below detection limits, which enables the restoration and preservation of immune system function, reduces HIV-associated morbidity, … Full story available on Benzinga.com
Corvus Pharmaceuticals Announces New Data Demonstrating CPI-818’s (ITK Inhibitor) Potential to Block HIV Latency Reversal 2023/02/21 12:00:00 GlobeNewswire
Findings may provide a treatment that enables discontinuation of HIV antiretroviral therapy by preventing re-emergence of the virus
Scholastic, Maxar Technologies And Some Other Big Stocks Moving Higher On Friday 2022/12/16 15:39:04 Kwhen Finance
4 Penny Stocks Insiders Are Buying: Getaround, Corvus Pharmaceuticals And More 2022/12/16 12:58:44 Benzinga
The Dow Jones closed lower by over 700 points on Thursday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company''s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga''s insider transactions platform. Intellicheck The Trade: Intellicheck, Inc. (NASDAQ: IDN ) President Garrett Gafke bought a total of 2,000 shares at an average price of $2.01. To acquire these shares, it cost around $4.02 thousand. What’s Happening: The company’s stock dipped around 43% over the past six months. What Intellicheck Does: Intellicheck Inc is a … Full story available on Benzinga.com
Corvus Pharmaceuticals Inc. (CRVS) can beat the pack with these strategies 2022/11/11 12:00:00 US Post News
As of Thursday, Corvus Pharmaceuticals Inc.’s (NASDAQ:CRVS) stock closed at $0.83, up from $0.74 the previous day. While Corvus Pharmaceuticals Inc. has overperformed by 12.00%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, CRVS fell by -82.11%, with highs and lows ranging from $4.87 to $0.69, […]
Corvus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022 2022/03/03 21:30:00 GlobeNewswire
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT
Corvus Pharma initiates Phase 1/1b trial of CPI-818 for T-cell lymphomas in China 2022/01/14 11:19:54 Seeking Alpha
Corvus Pharmaceuticals'' (CRVS) partner Angel Pharmaceuticals has treated the first patient in its Phase 1/1b clinical trial of Corvus small molecule ITK inhibitor CPI-818 for
Analysts Expect Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) to Post -$0.22 EPS 2021/12/10 18:06:42 Dakota Financial News
Wall Street analysts forecast that Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) will report earnings per share (EPS) of ($0.22) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have made estimates for Corvus Pharmaceuticals earnings, with the lowest EPS estimate coming in at ($0.27) and the highest estimate coming in at ($0.17). Corvus Pharmaceuticals posted []
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Expected to Post Earnings of -$0.22 Per Share 2021/12/08 13:12:45 Transcript Daily
Equities analysts expect Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) to report earnings per share (EPS) of ($0.22) for the current quarter, Zacks reports. Zero analysts have made estimates for Corvus Pharmaceuticals earnings. The lowest EPS estimate is ($0.27) and the highest is ($0.17). Corvus Pharmaceuticals reported earnings of ($0.35) per share during the same quarter last year, []